Abstracts tagged "corticosteroids"

Abstract Number: 2784 • 2019 ACR/ARP Annual Meeting
Alterations in Inflammatory, TNF-Superfamily, and IFN-Associated Chemokines Precede Clinical Changes in SLEDAI After Methylprednisolone Treatment of SLE Patients
Melissa E. Munroe¹, Carla J. Guthridge ¹, Sarah Kleckner ¹, Ly Tran ², Joel Guthridge ³, Debra J. Zack ⁴, Judith James ³ and Joan T. Merrill ⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Xencor, Inc., San Diego, CA, ⁵Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is typified by a wide spectrum of clinical manifestations and immune dysregulation. Corticosteroids are almost universally effective, but marked by unacceptable side effects.…
Abstract Number: 2773 • 2018 ACR/ARHP Annual Meeting
Diagnostic and Therapeutic Management of a Suspected Case of GCA: An Opinion Survey
Henri Guillet¹, Raphaël Porcher², Alain Saraux³, Loïc Guillevin⁴, Luc Mouthon⁴ and Alexis Régent⁴, ¹Département d'aval des urgences, CHU Henri Mondor, Créteil, France, ²Université Paris Descartes Sorbonne Paris, Paris, France, ³Rheumatology, CHU Brest, Brest, France, ⁴Institut Cochin, INSERM U1016, CNRS UMR 8104, PARIS, France
Background/Purpose: Giant-cell arteritis (GCA) is the most common vasculitis. Specialists have formulated recommendations on how to manage a patient with a possible diagnosis of GCA.…
Abstract Number: 462 • 2018 ACR/ARHP Annual Meeting
Steroid Use in Pediatric Proliferative Lupus Nephritis
Nathalie Chalhoub¹, Jianghong Deng², Natasha M. Ruth³, Stacy P. Ardoin⁴, Mileka Gilbert⁵, Theresa Hennard⁶, Linda Hiraki⁷, Paul T. Jensen⁸, Andrea M. Knight⁹, Rebecca Kunder¹⁰, Laura Lewandowski¹¹, Siok Hoon Lily Lim¹², Angela Merritt¹³, Sonia Iqbal Savani¹⁴, Mary Beth Son¹⁵, Emily von Scheven¹⁶, Scott E. Wenderfer¹⁷ and Hermine I. Brunner⁶, ¹Division of Immunology, Allergy, and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Division of Rheumatology, Beijing Children’s Hospital and Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, ⁵Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ⁸Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ⁹Division of Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰Gilead Sciences, Inc, Redwood City, CA, ¹¹NIAMS/NIH, Bethesda, MD, ¹²Children's Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, MB, Canada, ¹³Pediatric Rheumatology, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴Medical University of South Carolina, Charleston, SC, ¹⁵Boston Children's Hospital, Harvard Medical School, Brookline, MA, ¹⁶Pediatric Rheumatology, University of California San Francisco, San Francisco, CA, ¹⁷Pediatrics-Renal, Baylor College of Medicine, Houston, TX
Background/Purpose: Corticosteroids (CS) are the mainstay of childhood-onset lupus (cSLE) and proliferative lupus nephritis (LN) therapy. However, there are no widely accepted CS dosing regimens…
Abstract Number: 478 • 2018 ACR/ARHP Annual Meeting
Evidence Based Recommendations for Corticosteroid Tapering/Discontinuation in New Onset Juvenile Dermatomyositis Patients: Results from the Paediatric Rheumatology International Trials Organisation
Gabriella Giancane¹, Claudio Lavarello², Angela Pistorio², Francesco Zulian², Bo Magnusson³, Tadej Avcin², Fabrizia Corona², Valeria Gerloni², Serena Pastore², Roberto Marini², Silvana Martino², Anne Pagnier⁴, Michel Rodiere², Christine Soler², Valda Stanevicha², Rebecca ten Cate², Yosef Uziel², Jelena Vojinovic², Elena Fueri², Angelo Ravelli⁵, Alberto Martini⁶ and Nicola Ruperto⁷, ¹Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genoa, Italy, ²Istituto Giannina Gaslini - Clinica Pediatrica e Reumatologia - PRINTO, Genoa, Italy, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Istituto Giannina Gaslini - Clinica Pediatrica e Reumatologia - PRINTO, Genova, Italy, ⁵Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genova, Italy, ⁶Universita di Genova Pediatria II, Genova, Italy, ⁷Istituto Giannina Gaslini - Clinica Pediatrica e Reumatologia, Genoa, Italy
Background/Purpose: At present no clear evidence based guidelines exist to standardize the tapering and discontinuation of corticosteroids (CS) in juvenile dermatomyositis (JDM). Aim of our…
Abstract Number: 621 • 2018 ACR/ARHP Annual Meeting
Practical Optimization of Methotrexate Dose Improves Disease Control of Rheumatoid Arthritis Despite Reduction or Discontinuation of Oral Glucocorticoids
Shintaro Hirata¹, Kei Araki¹, Hiroki Kohno¹, Kazutoshi Yukawa¹, Tadahiro Tokunaga¹, Tatsuomi Kuranobu¹, Katsuhiro Oi¹, Yusuke Yoshida¹, Tomohiro Sugimoto¹, Keisuke Oda^1,2, Takaki Nojima^1,3 and Eiji Sugiyama¹, ¹Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ²Hiroshima Clinic, Hiroshima, Japan, ³Nojima Internal Medicine Clinic, Hiroshima, Japan
Background/Purpose: Short-term glucocorticoids (GCs) along with methotrexate (MTX) has been recommended for newly onset patients with rheumatoid arthritis (RA) in EULAR recommendation 2016. However, it…
Abstract Number: 712 • 2018 ACR/ARHP Annual Meeting
Higher Prednisolone Dose during Treatment of Tuberculosis Correlates with Mortality during Tuberculosis Treatment in Systemic Lupus Erythematosus Patients: A Retrospective Cohort Study
Chiao-Feng Cheng, Cheng-Hsun Lu, Song-Chou Hsieh and Ko-Jen Li, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Tuberculosis (TB) has complex interplay with systemic lupus erythematosus (SLE). In addition, SLE, corticosteroid, and immunosuppressants are associated with TB infection. However, the prognostic…
Abstract Number: 1371 • 2018 ACR/ARHP Annual Meeting
Systemic Exposure of Triamcinolone Acetonide Following Bilateral Injection of Extended-Release Triamcinolone Acetonide and Standard Triamcinolone in Patients with Bilateral Knee Osteoarthritis
Alan J. Kivitz¹, Louis Kwong², Tammi Shlotzhauer³, Joelle Lufkin⁴, Teresa Curto⁵ and Scott Kelley⁴, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Department of Orthopaedic Surgery, Harbor-UCLA Medical Center, Torrance, CA, ³Rochester Clinical Research, Inc., Rochester, NY, ⁴Flexion Therapeutics, Inc., Burlington, MA, ⁵Cytel Inc., Waltham, MA
Background/Purpose: Current ACR guidelines recommend the use of IACS for short-term acute pain relief in patients (pts) with knee OA.1 Bilateral knee OA can occur…
Abstract Number: 1913 • 2018 ACR/ARHP Annual Meeting
Management of Ventricular Tachycardia and Cardiomyopathy in the Rheumatologist World: A Retrospective Review of Diagnostic Tools and Treatment Decisions for Cardiac Sarcoidosis
Saba Ziaee¹, Siri Kunchakarra², Cara Joyce³, Mark Rabbat⁴ and Rochella A. Ostrowski⁵, ¹Loyola University Medical Center, Maywood, IL, ²Cardiology, Loyola University Medical Center, Maywood, IL, ³Clinical Research Office, Loyola University Medical Center, Maywood, IL, ⁴Division of Cardiology, Loyola University Medical Center, Maywood, IL, ⁵Division of Rheumatology, Loyola University Medical Center, Maywood, IL
Background/Purpose: Cardiac sarcoidosis has been noted in 2-7% of patients with sarcoidosis. However, the incidence is >20% based on necropsy data. Given the poor yield…
Abstract Number: 2190 • 2018 ACR/ARHP Annual Meeting
Means of Collaboration between Ophthalmologists, Rheumatologists and Internists in the Management of Non-Infectious Uveitis: A Nationwide Study
Magali Pacanowski Fournier¹, Antoine Brezin², Christophe Chiquet Sr.³, David Saadoun⁴, Jeremie Sellam⁵, Patrice Cacoub⁶, Pascal Sève⁷, Bahram Bodaghi Sr.⁸ and Laurent Kodjikian Sr.^9,10,11, ¹medical department, Magali Pacanowski Fournier is employee of AbbVie and own AbbVie stock, Rungis, France, ²Ophtalmology, Referral Center for Rare Ophthalmological Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, ophtalmology, France, Paris, France, ³ophtalmology, CHU-Grenoble-Alpes, La Tronche, France, ⁴Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, ⁵AP-HP Saint-Antoine hospital, Service de Rhumatologie, Inserm UMRS_938, Paris, France, ⁶Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, Paris, France, ⁷Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁸ophtalmology, Hôpital La Pitié-Salpêtrière; Université Sorbonne, paris, France, ⁹ophtalmology, Chu de La Croix-Rousse, hospices civils de Lyon, Lyon, France, ¹⁰université Claude Bernard lyon 1, villeurbanne, France, ¹¹UMR-CNRS 5510 Matéis, villeurbanne, France
Background/Purpose: When uveitis is believed to be part of an underlying systemic disease or when a systemic treatment is required, a multi-disciplinary approach is usually…
Abstract Number: 2191 • 2018 ACR/ARHP Annual Meeting
Safety of Ultrasound-Guided Injections Using Local Puncture Site Sterility
Suzan Jaradat¹, Maheswari Muruganandam², Noelle Rolle², Wilmer Sibbitt Jr.³, William Hayward⁴, N. Suzanne Emil³, Monthida Fangtham³, Roderick Fields³ and Arthur Bankhurst³, ¹Internal Medicine, University of New Mexico Health Sciences Center, ALBUQUERQUE, NM, ²University of New Mexico Health Sciences Center, ALBUQUERQUE, NM, ³Rheumatology, University of New Mexico Health Sciences Center, Albuquerque, NM, ⁴The Department of Exercise and Sport Sciences, New Mexico Highlands University, Las Vegas, NM
Background/Purpose: Ultrasound (US)-guided injections in musculoskeletal medicine typically utilize either local puncture site sterility or conventional surgical sterility. We report on the safety and complications…
Abstract Number: 2198 • 2018 ACR/ARHP Annual Meeting
Evaluation of 18F-Fluorodeoxyglucose PET-CT Score at Baseline on the Therapeutic Response to Prednisone in Polymyalgia Rheumatica: A Retrospective Study
Nicolas Giraud¹, Maxime Sondag², Aline Charpentier², Hatem Boulahdour³, Clément Prati^4,5, Daniel Wendling^6,7 and Frank Verhoeven⁸, ¹Rheumatology, CHU de Besançon, Besançon, France, ²rheumatology, CHU de Besançon, Besancon, France, ³CHU de Besançon, Besançon, France, ⁴EA 4267 FDE, FHU INCREASE, Université de Bourgogne Franche Comté, Besancon, France, ⁵Rheumatology, University Hospital - Bourgogne Franche Comté University, Besancon, France, ⁶Rheumatology, University Hospital - Bourgogne Franche Comté University, Besançon, France, ⁷EA 4266, Univ. Bourgogne Franche-Comté, F-25000 Besançon, France, F-25000 Besançon, France, ⁸EA 4267 PEPITE, Université de Bourgogne Franche Comté, Besançon, France
Background/Purpose: To evaluate the impact of 18F-fluorodeoxyglucose PET-CT (FDG-PET/CT) score at baseline, on the therapeutic response to prednisone, in patients with polymyalgia rheumatica (PMR). Methods:…
Abstract Number: 2390 • 2018 ACR/ARHP Annual Meeting
Incidence of and Risk Factors for Adrenal Suppression Following Ultrasound-Guided Intra-Articular Corticosteroid Injection with Triamcinolone Acetonide in Juvenile Idiopathic Arthritis
Katherine K Ngo¹, Angelina Bernier¹, Melissa E Elder², Renee F Modica² and Akaluck Thatayatikom¹, ¹Pediatrics, University of Florida, Gainesville, FL, ²Department of Pediatrics, University of Florida, Gainesville, FL
Background/Purpose: Intra-articular corticosteroid injection (IACI) is routinely used in juvenile idiopathic arthritis (JIA) with oligoarticular disease and as adjunct therapy for other types of JIA.…
Abstract Number: 2139 • 2017 ACR/ARHP Annual Meeting
Analysis of Required Dose of Corticosteroid As Maintenance Therapy and Related Factors in Patients with Polymyositis/Dermatomyositis
Eri Watanabe¹, Takahisa gono¹, Shinji Watanabe¹, Hiroki Yabe¹, Masataka Kuwana² and Chihiro Terai¹, ¹Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: PM and DM are inflammatory myopathies, sometimes complicated by interstitial lung disease (ILD), myocarditis, arthritis, and malignancies. The intensity of immunosuppressive therapies depends on…
Abstract Number: 2319 • 2017 ACR/ARHP Annual Meeting
Bradycardia after High-Dose Solu-Medrol
Deirdre De Ranieri¹ and Umesh Dyamenahalli², ¹Pediatric Rheumatology, The University of Chicago Medicine, Chicago, IL, ²Pediatric Cardiology, University of Chicago, Chicago, IL
Background/Purpose: Methylprednisolone (MP) in both high dose (2mg/kg or higher) and pulse dose (30mg/kg up to 1000mg) is often used to treat patients with connective…
Abstract Number: 2394 • 2017 ACR/ARHP Annual Meeting
Differential Effect of Corticosteroids and Biological Dmards on Five-Year Radiographic Progression in Rheumatoid Arthritis: Results from a Weighted Cumulative Exposure Model Developed on the Espoir Cohort
Baptiste Louveau¹, Yann De Rycke¹, Alexandre Lafourcade¹, Alain Saraux², Francis Guillemin³, Florence Tubach⁴, Bruno Fautrel⁵ and David Hajage¹, ¹APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 75018 75013, Paris, France, Paris, France, ²Rheumatology Department, Rheumatology Department, CHU de la Cavale Blanche, Brest, France, Brest Cedex, France, ³University of Lorraine, Nancy, France, Nancy, France, ⁴Université Pierre et Marie Curie (UPMC)-Paris 6; APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 75018 75013, Paris, France, Paris, France, ⁵UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France
Background/Purpose: In rheumatoid arthritis (RA), a strategic approach to achieve low-disease activity or remission is now recommended. Controlling joint damage is thus an important concern…

« Previous Page
1
…
6
7
8
9
10
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].